1. NAFLD and NASH in Europe and Canada

2. NAFLD: Spectrum of Disease and Clinical Outcomes

3. The Changing Face of Liver Disease in Europe

4. NAFLD and Cardiometabolic Complications

5. Prevalence of NAFLD in Europe

6. Why Are NAFLD and NASH Under-Recorded?

7. Roles of Diabetes and Obesity in NAFLD

8. Prevalence of NAFLD in Canada

9. NAFLD and NASH in Australia

10. Australia's NAFLD Problem

11. A Snapshot of Obesity in Australia

12. Increasing Incidence of NASH as an Indication for LT

13. Natural History of NAFLD: A Multinational Cohort Study

14. Natural History of NAFLD: A Multinational Cohort Study Findings

15. Implications for Australia

16. NAFLD and NASH: The Global Epidemic

17. Obesity: At the Root of the Problem

18. NAFLD: A Spectrum of Disease

19. NAFLD and NASH: A Global Epidemic

20. Multiple Clinical Outcomes of NAFLD and NASH

21. Evidence for Progression of NASH

22. Forecast for Progression of NAFLD in 2015 to 2030

23. Forecast for Progression of NAFLD in 2015 to 2030 (cont)

24. NAFLD Is Associated With Multiple Conditions

25. Improvement in Fibrosis Improves Quality of Life

26. NASH Associated With High Lifetime Economic Burden

27. Strategies to Decrease NASH Prevalence It Begins With Identifying Patients at Risk

28. Off-Label Pharmacologic Treatments

29. Targets in the Treatment Pipeline

30. Drugs in Phase 2 and Phase 3 Trials for NASH

31. Drugs in Phase 3 Trials for NASH

32. REGENERATE: Positive Results of OCA Treatment for NASH

33. Summary: NASH

34. Abbreviations

35. Abbreviations (cont)